In women with female sexual dysfunction, the Female Sexual Function Index rose by 5.35 in pooled drug treatment arms (including intranasal oxytocin) and by 3.62 in placebo arms.
In plain wordsIn women with sexual dysfunction, scores rose by 5.35 points with a mix of drugs, intranasal oxytocin among them, and by 3.62 points with placebo.
- Peptide
- Oxytocin
- Outcome
- IncreaseFemale Sexual Function Index change in pooled treatment arms
- Study
n = 2,236
- Outcome group
- Sexual function · Reproductive and sexual health
Measurements
- FSFI change
- 5.35 FSFI points
- pooled treatment arms
Source sentences
The treatment arm had a corresponding increase of 5.35 (95% CI 4.13-6.57).
1 context sentence(design, population, supporting numbers)
Two thousand two hundred thirty-six women were in the treatment arm of the respective studies and received various pharmacologic interventions including flibanserin, bupropion, onabotulinum toxin A, intravaginal prasterone, intranasal oxytocin, ospemifene, and bremelanotide.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.